Oxford BioMedica PLC (OXBDF)

[marcusl2]

The London, United Kingdom-based company plans to raise $200 million by offering 13.3 million ADSs at a price range of $14 to $16. At the midpoint of the proposed range, Orchard Therapeutics would command a fully diluted market value of $1.4 billion.

Oxford BioMedica currently owns 1,111,924 shares in Orchard Therapeutics (pre any share capital reorganisation which may be undertaken as part of the IPO process).

Additionally, Oxford BioMedica will receive a low single-digit royalty on net sales of licensed products until January 31, 2039. In the event the products are used for compassionate use, these royalties are reduced by a mid-double-digit percentage. Orchard Therapeutics is also required to pay a set monthly fee to Oxford BioMedica in the event the Group's system for generating stable cell lines is used.